Skip to main content
Figure 1 | Journal of Translational Medicine

Figure 1

From: KSP inhibitor ARRY-520 as a substitute for Paclitaxel in Type I ovarian cancer cells

Figure 1

ARRY-520 significantly decreases the number of viable Type II EOC cells. The viability (in percentage, normalized to untreated cells) of EOC cells after treatment with increasing concentrations of ARRY-520 for (a) 24 and (b) 48 hours. Data were compiled from at least three independent experiments, each done in triplicate. Type I cells – R182, 01–19b, R1140; Type II cells – A2780, CP70, 01–28; dotted line corresponds to 50% viability.

Back to article page